Results 221 to 230 of about 248,426 (329)
Short‐ and Long‐Term Outcomes of Open, Laparoscopic, and Robot‐Assisted Surgery for Rectal Cancer
Robot‐assisted rectal resection demonstrated superior short and long‐term outcomes compared to laparoscopic and open approaches. ABSTRACT Background Robot‐assisted surgery has short‐term benefits in rectal cancer surgery; however, its long‐term advantages remain unclear. This study compared short‐ and long‐term outcomes of open, laparoscopic, and robot‐
Marie Hanaoka+8 more
wiley +1 more source
This multi‐institutional, randomized, phase II trial aimed to investigate the long‐term survival outcomes of two versus three courses of DCF for locally advanced esophageal squamous cell carcinoma (ESCC). The 5‐year overall survival and progression‐free survival rates for the three and two course groups were 70.7% vs. 63.8% (hazard ratio (HR) = 0.91, p
Takahito Sugase+19 more
wiley +1 more source
Essential Updates 2023/2024: Recent Advances of Multimodal Approach in Patients for Gastric Cancer
ABSTRACT Gastric cancer remains a major global health burden, especially in East Asia. Recent years have brought significant advances in multimodal management, including surgery, perioperative chemotherapy, immunotherapy, and supportive care. This review summarizes key updates from 2023 to 2024, focusing on surgical innovations, perioperative systemic ...
Katsutoshi Shoda+3 more
wiley +1 more source
This study investigated the association between radiographic and pathological response assessments among patients with pancreatic cancer receiving neoadjuvant chemotherapy and neoadjuvant chemoradiotherapy. The present study revealed that discrepancies between radiographic and histological responses may differ according to the type of therapy ...
Satoru Miyahara+8 more
wiley +1 more source
ABSTRACT Background Neoadjuvant chemotherapy (NAC) has been extensively developed for locally advanced gastric cancer (GC). In Asia, S‐1‐based regimens, such as docetaxel, oxaliplatin, and S‐1 (DOS) and S‐1 and oxaliplatin (SOX), are expected to become the standard of care.
Kota Kawabata+9 more
wiley +1 more source
Accessing and Receiving Speech-Language Pathology Services at the Multidisciplinary Amyotrophic Lateral Sclerosis Clinic: An Exploratory Qualitative Study of Patient Experiences and Needs. [PDF]
Huynh A+5 more
europepmc +1 more source
How Evidence-Based Practice (E3BP) Informs Speech-Language Pathology for Primary Progressive Aphasia. [PDF]
Ruggero L, Croot K, Nickels L.
europepmc +1 more source